NCT07411729 Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
| NCT ID | NCT07411729 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Emerging Infectious Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2024-06-03 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Eligibility Criteria
Inclusion Criteria: * Adults (≥ 18 years old) hospitalized in one of the participating centers at Bicêtre or Paul Brousse hospitals, for whom residual biological samples are available as part of routine care in one or more participating hospital departments. * Covered by, or entitled to, the French social security system (excluding State Medical Aid - AME). * Patient or legal representative/trusted person informed about the registry and having provided written consent to participate. Exclusion Criteria: * Patients under judicial protection (guardianship or curatorship). * Patients deprived of liberty by judicial or administrative decision. * Patients not speaking French and not accompanied by a translator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07411729 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Emerging Infectious Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07411729 currently recruiting?
Yes, NCT07411729 is actively recruiting participants. Contact the research team at thierry.naas@aphp.fr for enrollment information.
Where is the NCT07411729 trial being conducted?
This trial is being conducted at Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre, France, Le Kremlin-Bicêtre, France and 6 additional locations.
Who is sponsoring the NCT07411729 clinical trial?
NCT07411729 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 800 participants.